当前位置: »论坛 › 科研专区 › 悬赏问答› P. Schmid, P.J. Wysocki, C.X. Ma, et al. Datopotamab ...

[已完结] P. Schmid, P.J. Wysocki, C.X. Ma, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, ...

求助已关闭

Ywaaa 发表于 2024-8-27 23:33:40 | 显示全部楼层 |阅读模式

悬赏10积分

P. Schmid, P.J. Wysocki, C.X. Ma, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. 2023 ESMO Abstract 379MO

使用道具捐赠获取积分应助有误反馈

全部回复0 显示全部楼层

发表回复

Ywaaa Lv.3

高级会员

发布
回复
积分
450

悬赏问答

30 Nizatidine versus placebo in gastro-oesophageal reflux disease: a 6-week, multicentre, randomised, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group

[已完结] P. Schmid, P.J. Wysocki, C.X. Ma, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, ...

发表回复

悬赏问答

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[已完结] P. Schmid, P.J. Wysocki, C.X. Ma, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, ... 一键复制

发表回复

悬赏问答

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[已完结] P. Schmid, P.J. Wysocki, C.X. Ma, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, ...